US 7300940
Integrin α-v β-3 antagonists for use in imaging and therapy
granted A61PA61P35/00
Quick answer
US patent 7300940 (Integrin α-v β-3 antagonists for use in imaging and therapy) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 48
- CPC classes
- A61P, A61P35/00